TrialThoracic cancer2022

Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1.

Takeshi Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.